<qa>  What is the mainstay of treatment for congenital hyperinsulinism?Congenital hyperinsulinism is a rare condition that can cause life-threatening hypoglycemia. Current treatment for congenital hyperinsulinism is often suboptimal, with diazoxide as the mainstay of treatment. Individuals who are not adequately treated with diazoxide may undergo pancreatectomy. Octreotide has been used with some success in congenital hyperinsulinism but there is limited data on pasireotide, the newest somatostatin receptor agonist, which, compared to octreotide, has 30-40 times greater affinity for somatostatin receptors 1 SSTR1 and 5 SSTR5, 5 times greater for somatostatin receptor 3 SSTR3 and a comparable affinity for somatostatin receptor 2 SSTR2. 